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ABSTRACT
Physical activity initiates a wide range of multi-systemic adaptations that promote mental and physical
health. Recent work demonstrated that exercise triggers the release of extracellular vesicles (EVs) into
the circulation, possibly contributing to exercise-associated adaptive systemic signalling. Circulating EVs
comprise a heterogeneous collection of different EV-subclasses released from various cell types. So far,
a comprehensive picture of the parental and target cell types, EV-subpopulation diversity and functional
properties of EVs released during exercise (ExerVs) is lacking. Here, we performed a detailed EV-
phenotyping analysis to explore the cellular origin and potential subtypes of ExerVs.
Healthy male athletes were subjected to an incremental cycling test until exhaustion and blood was
drawn before, during, and immediately after the test. Analysis of total blood plasma by EV Array
suggested endothelial and leukocyte characteristics of ExerVs. We further purified ExerVs from plasma
by size exclusion chromatography as well as CD9-, CD63- or CD81-immunobead isolation to examine
ExerV-subclass dynamics. EV-marker analysis demonstrated increasing EV-levels during cycling exercise,
with highest levels at peak exercise in all EV-subclasses analysed. Phenotyping of ExerVs using
a multiplexed flow-cytometry platform revealed a pattern of cell surface markers associated with
ExerVs and identified lymphocytes (CD4, CD8), monocytes (CD14), platelets (CD41, CD42, CD62P),
endothelial cells (CD105, CD146) and antigen presenting cells (MHC-II) as ExerV-parental cells. We
conclude that multiple cell types associated with the circulatory system contribute to a pool of
heterogeneous ExerVs, which may be involved in exercise-related signalling mechanisms and tissue
crosstalk.
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Introduction
Physical exercise is eliciting a multisystemic response,
guiding specific adaptation processes known to promote
overall health status and to protect from lifestyle disease.
In addition to increased cardiovascular and metabolic
demands, changes in immune-related factors such as
leukocyte distribution as well as hormone and cytokine
levels are prevailing in the acute phase. Subsequently,
multiple organs and cell populations are engaged in tissue
crosstalk maintaining whole body homeostasis [1–3].
Although the role of myokines and adipokines released
from skeletal muscle and adipose tissue is well described
[4,5], many of the factors mediating systemic adaptation
and the long-term beneficial effects of exercise still
remain unexplored [3].
Extracellular vesicles (EVs) have evolved as key
players in cell-cell communication mediating cross-
organ signalling and tissue homeostasis [6,7]. EVs
are actively released from cells and deliver bioactive
cargo such as enzymes, cytokines and miRNAs to
target cells in paracrine fashion or via the circulation.
Blood contains a heterogeneous mixture of EVs, com-
prising apoptotic bodies, microvesicles shedding from
the plasma membrane and exosomes released from
the lumen of multi-vesicular bodies. In the absence
of markers and purification strategies clearly distin-
guishing these subtypes, EVs of unclear subcellular
origin can be grouped according to size into large
EVs and small EVs [8,9].
Recent work including our own has demonstrated that
during exercise, EVs are released into the circulation in
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humans as well as rodents [10–13]. Proteomic character-
ization of a crude EV-fraction derived from exercising
humans suggested that these EVs at least partly reflect
small EVs and comprise muscle-derived EVs delivering
myokines to the liver [14]. Furthermore, a substantial
body of literature describes the influence of exercise on
the appearance of larger endothelial and platelet-derived
EVs (often referred to as microparticles) in the clinical
context of cardiovascular and metabolic disease as well as
coagulation (reviewed in [15–17]). Together, these studies
raise the tempting concept that EVsmaymediate signalling
processes associated with the exercise adaptive response
and furthermore, could evolve as biomarkers or even ther-
apeutic vehicles for sedentary lifestyle-associated diseases.
Most likely, several tissues contribute to EVs released
during exercise establishing an intricate signalling net-
work. To fully explore the role of circulating EVs in
exercise-mediated tissue crosstalk, it will be essential to
elucidate the cell types of origin, the relevant EV-subtypes
as well as their molecular phenotype and functional
properties. EV-specification is achieved by genuine EV-
markers in combination with EV-components defining
the cell-type of origin. Among the genuine EV-markers,
the tetraspanins CD9 and CD63 are ubiquitously asso-
ciated with most EV-types, while CD81, Tsg101 and
Syntenin are considered to be more prevalent in small
EVs and exosomes [9,18]. Immuno-isolation of EVs
based on the surface expression of CD9, CD63 or CD81
has the potential power to provide further insight into the
presence of distinct EV-subsets defined by individual
tetraspanins.
Here, we performed a multiplexed phenotyping of
EVs released into the circulation during physical exer-
cise (ExerVs) aiming at a more detailed view on their
origin and the contributing EV-subtypes. ExerVs iso-
lated by size exclusion chromatography (SEC) were
compared to immuno-isolated EVs defined by tetra-
spanin expression. The results demonstrate that ExerVs
constitute a mixture of CD9, CD63 and CD81-positive
EVs. A significant proportion of ExerVs was derived
from leukocytes, platelets and endothelial cells, impli-
cating different roles in exercise-associated tissue cross-
talk such as tissue regeneration, immune regulation,
coagulation or angiogenesis.
Material and methods
Ethical approval
All experimental procedures were approved by the
Human Ethics Committee Rhineland-Palatine and
conformed to the standards of the Declaration of
Helsinki of the World Medical Association. All subjects
were informed orally and in writing about the proce-
dures and the aim of the study and gave written con-
sent to participate.
Subjects and exercise setting
Twenty-one healthy male athletes voluntarily partici-
pated in this exercise study. Inclusion criteria were non-
smoking and no medication. After analysis of three pilot
subjects, in favour of standardization, all tests were con-
ducted between 8 and 10 am after a minimum of 8 h of
overnight fasting, applying the same exercise protocol.
Participants were told to abstain from training at the day
before and morning prior to the test, which included to
choose a non-exhaustive way to arrive at the place where
the exercise tests were carried out. Additionally, partici-
pants were kept at rest at least for 30 min prior to the first
venous and capillary blood drawing and the subsequent
exercise test. One participant was excluded from the
statistical analysis of vesiclemarker changes due to having
eaten a fat-richmeal several hours before the exercise test.
However, the data were used to report on the influence of
the intake of a high-fat meal on the analysis of ExerVs.
The athletes performed an incremental cycling test
starting at 40 Watt, increasing power by 40 Watt every
3 min until exhaustion indicated subjectively by the par-
ticipant. The level of subjective exhaustion was assessed
by the 6 to 20 Borg-Scale after each step [19]. During the
test, spiroergometric (respiratory) data as well as heart
rate were continuously recorded. At a respiratory
exchange ratio of 0.9, determined as the volume of CO2
exhaled divided by volume of O2 taken up inmedian over
the course of 15 breathing cycles, the second venous
blood drawing was started (RQ 0.9). The submaximal
exercise level at RQ 0.9 reflects a subjective load that is
about equivalent to a typical aerobic exercise training at
medium intensity for trained as well as untrained persons
and independent of their nutritional status [20].
Therefore, analysis of samples received at RQ 0.9 intro-
duces a level of exertion during exercise, which is roughly
comparable amongst individuals.
After completion of the test, the third venous blood
drawing was performed within 2 min after exhaustion.
For venous blood drawing, 33 ml of blood were taken
from themedian cubital vein with a Safety-Multifly® needle
(0.8 × 19 mm) (Sarstedt, Nümbrecht, Germany) and col-
lected in tripotassium-EDTA covered Monovettes®
(Sarstedt, Nümbrecht, Germany) and S-Monovettes®
(Z-Gel, for serum analysis of non-EV parameters)
(Sarstedt, Nümbrecht, Germany), respectively.
Next to venous blood sampling, capillary blood was
collected prior to the test, at the end of each 3 min level
and immediately after exhaustion. For lactate
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measurement, 20 μl of capillary blood were collected
from the earlobe. For cfDNA samples, 30 µl of capillary
blood were collected with a dipotassium-EDTA covered
Microvette CB 300 (Sarstedt, Nümbrecht, Germany)
from the fingertip.
Determination of analytical parameters
Venous blood in serum-tubes and EDTA-tubes were
used to determine metabolic parameters and blood cell
counts in routine diagnostics. Blood lactate levels were
measured with the lactate analyser Biosen 5130 (EKF
Diagnostics, Magdeburg, Germany). Respiratory gas
exchange analysis (spiroergometry) was carried out
using Bluecherry (Geratherm Respiratory GmbH, Bad
Kissingen, Germany), and individual anaerobic thresh-
old (IAT) was determined at a net increase of lactate
concentration of 1.0 mmol/l above lactate concentra-
tion at lactate threshold [21]. For cfDNA analysis,
capillary blood was centrifuged 2 min at 1,600 x g at
4°C, and nucleic acid concentration was measured in
diluted plasma (1:10 in H2O) by direct quantitative
real-time PCR of the L1PA2-repeat as previously
described [22], with slight modifications. The 90 bp
L1PA2 fragment was amplified using CFX384 BioRad
cycler with 2 min 98°C, followed by 10 s 95°C and 10
s 64°C for 35 cycles. 2 µl of diluted plasma were mixed
with 13 µl of Mastermix [final concentrations: Velocity
Polymerase 0.6 u, 1.2x Hifi Buffer (Bioline,
Luckenwalde, Germany), 0.15x SYBR Green, 0.001x
FITC, 0.3 mM dNTPs, 0.15 µM primers] for triplicates
in 5 µl final volume.
Venous plasma preparation
Platelet-free venous blood plasma used for EV charac-
terization was prepared considering the guidelines of
the international society for thrombosis and haemos-
tasis [23] and further recommendations for pre-
analytical parameters on EV analysis [24]. After blood
drawing, venous EDTA-blood was kept vertically on
room temperature avoiding agitation. First centrifuga-
tion of 15 min 2,500 x g at room temperature was
performed within 15 min after each blood collection.
Plasma was collected and subjected to a second centri-
fugation of 15 min 2,500 x g at room temperature to
obtain platelet-free plasma. Platelet-free plasma was
kept on ice until EV preparation or frozen at −80°C.
The gap between blood draw and first centrifugation
was determined by the longitudinal design including
short sample collection intervals between pre, RQ 0.9
and post (below 15 min) and was kept constant
between the samples.
EV Array
EV surface marker profile in the plasma of exercising
humans was determined using the EV Array, as
described by [25]. 10 µl of plasma from 10 of the
subjects was used to analyse the presence of the follow-
ing 41 marker proteins: Alix (clone #3A9, Biolegend,
San Diego, USA), Annexin V (polyclonal, AF399, R&D
Systems, Minneapolis, USA, Minneapolis, USA), Apo
E (#395,004, R&D Systems, Minneapolis, USA), CAIX
(#2D3, Abcam, Cambridge, UK), Cathepsin
D (polyclonal, AF1014, R&D Systems, Minneapolis,
USA), CAXII (#315,602, R&D Systems, Minneapolis,
USA), CD14 (#M5E2, BD Biosciences, San Jose, USA),
CD142 (#323,514, R&D Systems, Minneapolis, USA),
CD146 (#P1H1, Abcam, Cambridge, UK), CD151
(#210,127, R&D Systems, Minneapolis, USA), CD171
(polyclonal, HPA005830, Sigma-Aldrich, St. Louis,
USA), CD235a (#R10, R&D Systems, Minneapolis,
USA), CD31 (polyclonal, AF806, R&D Systems,
Minneapolis, USA), CD4 (#34,930, R&D Systems,
Minneapolis, USA), CD42a (polyclonal, LS-C45240,
LS Bio, Seattle, USA), CD42b (#486,805, R&D
Systems, Minneapolis, USA), CD45 (#2D1, R&D
Systems, Minneapolis, USA), CD62E/P (#BBIG-E6,
R&D Systems, Minneapolis, USA), CD62E (1.2B6,
Thermo Scientific, Carlsbad, USA), CD63 (#MEM-
259, Bio-RAD, Hercules, CA, USA), CD81 (#1.3.3.22,
Ancell, Bayport, USA), CD82 (#423,524, R&D Systems,
Minneapolis, USA), CD8a (#37,006, R&D Systems,
Minneapolis, USA), CD9 (#SN4/C3–3A2, Ancell,
Bayport, USA), EpCAM (#0.N.277, Santa Cruz,
Dallas, USA), Flotillin-1 (polyclonal, ab41927, Abcam,
Cambridge, UK), GRP78 (#N-20, Santa Cruz, Dallas,
USA), HLA-ABC (#W6/32, Biolegend, San Diego,
USA), HLA-DR (#L243, Biolegend, San Diego, USA),
HLA-DRDPDQ (#HB-145, Loke Diagnostics, Aarhus,
Denmark), Hsp70 (polyclonal, SPA-811, Assay design,
Michigan, USA), Hsp90 (polyclonal, ab13494, Abcam,
Cambridge, UK), ICAM-1 (#R6.5, eBioscience, San
Diego, USA), LAMP-1 (#508,921, R&D Systems,
Minneapolis, USA), LFA1 (#HI111, Ab Biotec, San
Diego, USA), TGFb1 (#A75–2, BD Pharmingen, San
Diego, USA), TLR3 (#TLR3.7, Santa Cruz, Dallas,
USA), tPA (polyclonal, AF7449, R&D Systems,
Minneapolis, USA), TSG101 (polyclonal, ab117627,
Abcam, Cambridge, UK), VE-Cadherin (polyclonal,
AF938, R&D Systems, Minneapolis, USA), VEGFR2
(#7D4–6, Biolegend, San Diego, USA).
Log base-2 normalized EV Array raw data analysis
was restricted to those candidates that reached an
average fluorescence level above the limit of detection
(LOD) as defined by a fluorescence higher than 3-times
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the standard deviation above the fluorescence of both
of the controls. As a first control, we used the fluores-
cence obtained by measuring a blank sample (washing
buffer without plasma). As a second more stringent
control, we used the fluorescence obtained from each
plasma sample in the microarray spots not coated with
a capture antibody.
EV isolation
EV-analysis was performed on EDTA-plasma samples.
EV isolation by size exclusion chromatography (SEC)
was implemented using self-made columns according
to Boing [26] with minor modifications. Sepharose CL-
2B (Sigma-Aldrich, St. Louis, USA) columns were
packed in a 10 ml-syringe placing a 0.22 µm PES-
filter membrane at the bottom of the syringe. After
washing of the column with PBS, 2 ml of platelet-free
plasma were loaded on the column and 1 ml fractions
were collected. Single fractions were analysed for par-
ticle count using nanoparticle tracking analysis, protein
content using the Novagen BCA Protein Assay Kit
(Merck Millipore, Darmstadt, Germany) and presence
of vesicular and non-vesicular markers by Western
blotting. Fractions 4 to 6 were considered EV-rich
while plasma protein- and lipoprotein-poor, pooled
and 30x concentrated in 30 kDa Amicon Ultra-4 ml
filter devices (Merck Millipore, Darmstadt, Germany)
to obtain 100 µl of SEC-EVs.
EV preparation by immunobead isolation was per-
formed using the CD9-, CD63- or the CD81-Exosome
Isolation Kit according to the manufacturer’s protocol
(Miltenyi Biotec, Bergisch-Gladbach, Germany). 2 ml
of platelet-free plasma were used as starting material,
and the elution volume was 130 µl of CD9+, CD63+
and CD81+EVs, respectively. All isolated EV samples
were kept on ice until further treatment.
The sample volume that can be retrieved from one
subject within the setting (three time points of blood
drawing) is limited to around 6 ml of plasma per time
point and allowed a parallel analysis of three different
isolation procedures at maximum. Hence, not all sub-
jects are reflected as a data point in each of the analyses.
Nanoparticle tracking analysis (NTA)
SEC-isolated EVs were analysed using the Nanosight
LM10 system (camera model Hamamatsu C11440-50B/
A11893-02) equipped with a 532 nm laser and
a syringe pump as well as the Nanosight 2.3 software
(Malvern, Herrenberg, Germany) at 23°C (temperature
controlled). The following settings were used: camera
control in standard mode (camera level 14), particle
detection in standard mode (detection threshold 8 and
minimum expected particle size auto), and script con-
trol (Repeatstart, Syringeload 500, Delay 5, Syringestop,
Delay 15, Capture 30 and Repeat 4). Five videos of 30
s were recorded, particles were tracked (batch process)
and average values were formed. EV samples were
diluted in particle-free PBS to obtain a particle concen-
tration of 3–10 × 108 particles/ml. Measurements were
verified utilizing silica microspheres (Polysciences,
Warrington, PA, USA) with a size of 100 nm as
described by Gardiner [27].
Western blotting (WB)
SEC fractions or immunobead-isolated EVs normalized in
volume to the starting volume of plasma were mixed with
sample buffer (200 mM Tris-HCL (pH 6.8); 10% SDS;
0.4% bromophenol blue; 40% glycerol; 400mM DTT; for
CD9 and CD63 antibodies under non-reducing condi-
tions) and subjected to SDS-PAGE (8% or 12%) and WB
using PVDF-membranes. Membranes were blocked with
4% milk powder and 0.1% Tween in PBS and incubated
with primary and HRP-coupled secondary antibodies.
Subsequently, chemiluminescent detection and visualiza-
tion was implemented. If applicable, themembrane was re-
stained with a primary antibody for a different marker
protein. For semi-quantitative analysis of WB signals,
ImageJ software was used. Immuno-stainings showing
high background noise were not included in the semi-
quantitative analysis (e.g. presented CD9+EVs Syntenin
staining, Figure 6(a)) and, thus, are not represented as
data points in the quantitative data analysis.
The following antibodies were applied: CD9 (1:2000
dilution, clone #MM2/57, Merck Millipore, Darmstadt,
Germany), CD63 (1:500 dilution, #CBL553, Merck
Millipore, Darmstadt, Germany), CD81 (1:1000 dilution,
#B-11, Santa Cruz, Heidelberg, Germany), Syntenin
(1:2000 dilution, polyclonal, ab19903, Abcam,
Cambridge, UK), TSG101 (1:1000 dilution, #4A10,
GeneTex, Irvine, CA, USA), CD41 (1:1000 dilution,
#SZ.22, Santa Cruz, Heidelberg, Germany), SGCA (1:500
dilution, #D-7, Santa Cruz, Heidelberg, Germany), ApoA1
(1:200 dilution, #12C8, Santa Cruz, Heidelberg, Germany),
goat-anti-mouse-HRP (1:10,000 dilution, polyclonal,
115–035-166, Dianova, Hamburg, Germany), mouse-anti-
rabbit-HRP (1:10,000 dilution, #5A6-1D10, Dianova,
Hamburg, Germany).
Electron microscopy
SEC-EVs were fixed with 4% PFA and adhered to 100
mesh copper-grids for 5 min and analysed by transmis-
sion electron microscopy (EM) after 10 washes with
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a. dest. and embedding in 2% methylcellulose with
0.4% uranyl acetate.
Multiplex surface marker analysis
MACSPlex analysis was performed using the MACSPlex
Exosome, human, Kit (Miltenyi Biotect, Bergisch-
Gladbach, Germany) according to the kit specifications.
The overnight capture antibody incubation protocol was
applied, performing the detection with a combination of
CD9-, CD63- and CD81-APC antibodies. Throughout the
analysis, same sample volumes for the different time points
were used: 120 µl of SEC-EVs and 50 µl of CD9+EVs,
CD63+EVs or CD81+EVs. Flow cytometric analysis was
carried out on the MACSQuant Analyzer 10 with the
corresponding software (Miltenyi Biotec, Bergisch-
Gladbach, Germany). For further analysis, background
values of the control sample (PBS) of each run were sub-
tracted from the sample values. Surface marker values
below the corresponding control antibody included in the
kit, considered as measurement threshold, were regarded
as negative. For data series, where the RQ 0.9 and/or post-
exercise values were clearly above this threshold, pre values
were included despite being under the threshold; these
cases are explicitly marked in the results section.
Heatmap cluster analysis and statistical analysis of
marker changes
The heatmaps were produced using R (Version 3.5.0,
RStudio, Inc., Boston, USA) with the ComplexHeatmap
package (Version 1.18.1), clustering with Pearson corre-
lation [28].
For statistical analysis of marker changes in EV Array,
WB andMACSPlex, log normalized values were compared
by ANOVA across all three points in time related to
exercise (pre-exercise, RQ 0.9 and post-exercise).
A significant global F-test (p < 0.05) across all points in
time was followed by post-hoc testing using each pair’s
students t-testing. Post hoc p-values were Bonferroni-
corrected for two comparison (pre to RQ 0.9 and pre to
post), and a value of <0.05 was considered significant (* =
p < 0.05, ** = p < 0.01, *** = p < 0.001). For graphical
presentation of marker changes, data were transformed
back and fold changes are presented as geometric means
with individual subject results for WB analysis and 95%
confidence intervals for EV Array andMACSPlex analysis.
EV-TRACK
We have submitted all relevant data of our experiments to
the EV-TRACK knowledgebase (EV-TRACK ID:
EV180071) [29].
Results
Study design: acute exercise and sample collection
To assess the marker profile and the kinetics of EVs
released during physical activity, we performed
a comparative exercise study involving 21 active healthy
male subjects (age: 28.7 ± 4.2 y, BMI: 22.8 ± 2.0) who,
following overnight fasting, underwent an incremental
cycling test until exhaustion. Physiological parameters
of all subjects, including blood lactate, heart rate, oxygen
consumption, Borg values (subjective rate of perceived
CD9 CD81
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Figure 1. Exercise setting and study design. (a) Exemplary illustration of the incremental cycling test and time points of sample
collection. Diagram depicts blood lactate (black line) and cell-free DNA levels (cfDNA; grey line), measured every 3 min at each
increment. Lactate and cfDNA strongly increase after the individual anaerobic threshold (IAT, dashed vertical line) until exhaustion
of the subject. Venous blood was drawn before starting the test (pre), during the test at the respiratory quotient (RQ) 0.9 and
immediately at the end of exercise (post). (b) Outline of the combined experimental strategy to characterize EVs released during
exercise (ExerVs). Blood cell counts and metabolic parameters were assessed in venous blood samples taken at the three time points
indicated in (a). EV Array and cfDNA analysis were performed with unprocessed plasma. For WB and MACSPlex analysis, EVs were
purified from plasma by SEC or immuno-bead isolation using CD9-, CD63- or CD81-magnetic beads.
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exertion) and cfDNA kinetics (objective molecular mar-
ker for physical exhaustion [30]), were recorded (Figure 1
(a), Table 1). Venous blood for subsequent EV analysis
was drawn prior to the test (pre), during the test (RQ 0.9)
and immediately after exhaustion (post). Lactate and
cfDNA levels increased from pre (0.9 ± 0.2 mmol/l, 25
± 11.9 ng/ml) to RQ 0.9 (2.3 ± 1.1 mmol/l, 45.2 ± 25 ng/
ml) and finally to post-exercise (9.4 ± 2.8 mmol/l, 163.5 ±
90.2 ng/ml) roughly by 10-fold and sevenfold, respec-
tively. Blood cell counts and blood parameters, which
could have influenced EV analysis, were all within the
normal range at rest (Table 2). Leukocyte counts slightly
increased during exercise as previously reported [31]. We
further characterized EVs present in plasma and imple-
mented different isolation and characterization strategies
(Figure 1(b)), including size-exclusion chromatography
(SEC) purification and immuno-bead precipitation of
different EV-populations followed by WB and multi-
plexed marker analysis (EV Array, MACSPlex assay).
Although sample volume limitations did not permit par-
allel assessment of all the analysis techniques, the strategy
allowed a comprehensive view on the presence and
dynamics of EV-populations in the circulation of exercis-
ing humans. To designate EVs released during exercise,
we use the generic term ExerVs.
EV Array as initial indicator of ExerV-associated
marker dynamics
To reveal an indication of the potential changes in the
EV-marker profile during cycling exercise, we first
employed the EV Array technology, detecting EVs in
whole plasma based on antibody-mediated detection of
multiple customized cellular markers next to EV-
markers [32]. While several markers stayed below the
limit of detection (LOD) or remained constant during
exercise (not shown), a range of markers was identified
that displayed increased or decreased signal intensity
during exercise (Figure 2(a)). Among these, Alix,
CD14, CD142, HLA-ABC (MHC-I), ICAM-1, LAMP-
1 and tPA were found to exhibit a significant gradual
increase from pre over RQ 0.9 to post-exercise,
although the fold changes in signal intensity were mar-
ginal (Figure 2(b)). Elevation of these markers may
provide a first hint that ExerVs exhibit endosomal
characteristics and could be derived from leukocytes
and endothelial cells. However, the most prominent
EV-markers CD9, CD63, CD81 as well as Flot-1,
HSP70 and CD41b, which had been shown to increase
during cycling exercise before [12], were below the
detection threshold of the assay. These results indicate
that the EV Array may not be able to fully resolve
marker kinetics during the applied exercise setting,
possibly due to the high complexity of whole plasma
dominated by other components (e.g. albumin, immu-
noglobulins and lipoproteins). Thus, purification of
EVs prior to analysis appears essential to gain deeper
insight in the characteristics of ExerVs.
SEC-isolated ExerVs increase during exercise
To isolate EVs from the plasma of exercising subjects,
we first utilized size exclusion chromatography (SEC)
as a size-based purification strategy. SEC was recently
established as a method of EV-isolation from plasma
allowing separation of EVs from a large fraction of
lipoprotein particles and other plasma components
[26,33–35]. Consistently, particles with the size of
EVs eluted largely in fractions 4–6, while the mass of
protein eluted in later fractions (Figure 3(a)). Fractions
Table 1. Test parameters of the study subjects.
Time
(min)
Load
(Watt)
Load/weight
(Watt/kg) Borg Lactate (mmol/l) cfDNA (ng/ml) Heart rate (1/min) VO2 (ml/min/kg) IAT (Watt)
Pre - - - - 0.9 (0.2) 25 (11.9) 80.2 (14.4) 5 (1.1) 197.8
(49.4)RQ 0.9 14 (3.7) 201 (52.9) 2.7 (0.7) 14.6 (2.0) 2.3 (1.1) 45.2 (25.0) 145.4 (16.6) 33.7 (6.5)
Post 23.6 (2.8) 324.3 (49.5) 4.4 (0.8) 19.6 (0.6) 9.4 (2.8) 163.5 (90.2) 184.7 (8.5) 48.8 (6.5)
Values are given in mean ±SD, n = 21.
RQ respiratory quotient, cfDNA cell-free DNA, VO2 oxygen consumption [VO2 at post = maximal oxygen consumption), IAT individual anaerobic threshold
based on lactate accumulations according to [21].
Table 2. Lipoproteins and blood cell counts in exercising humans.
HDL-cholesterol
(mg/dl]
LDL-cholesterol
(mg/dl)
Erythrocytes
(T/l)
Platelets
(G/l)
Leukocytes
(G/l)
Monocytes
(G/l)
Band
neutrophils
(G/l)
Segmented
neutrophils
(G/l)
Lymphocytes
(G/l)
Pre 66.6 (16.4) 92.6 (21.8) 5.1 (0.3) 235.5 (49.4) 5.1 (1.3) 0.4 (0.2) 0.1 (0.2) 2.7 (1.0) 1.8 (0.7)
RQ 0.9 72.4 (20.6) 98.1 (22.6) 5.3 (0.3) 263.7 (53.6) 7.3 (1.7) 0.7 (0.3) 0.2 (0.5) 3.4 (1.2) 2.7 (0.9)
Post 73.8 (18.9) 100.2 (25.6) 5.3 (0.3) 297.0 (53.0) 8.5 (2.0) 0.7 (0.3) 0.2 (0.4) 4.0 (1.2) 3.3 (1.3)
Values are given in mean ±SD, n = 21.
RQ respiratory quotient, HDL high density lipoprotein, LDL low density lipoprotein, T/l 1012 cells per litre, G/l 109 cells per litre.
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4–6 indeed contained EV-proteins such as CD9, CD63,
CD81 or the platelet EV-marker CD41b (Figure 3(b)).
Moreover, vesicular structures with the size of small
EVs were identified in these fractions by transmission
electron microscopy (Figure 3(c)). We further pooled
the EV-rich fractions 4-6 (SEC-EVs), which were not
completely free of lipoproteins as a small fraction of
Apolipoprotein A1 (ApoA1) still was detectable in
fraction 6 (Figure 3(b)). NTA analysis of SEC-EVs
revealed a mean particle size of 106.3 ± 4.5 nm and
a mode size of 89.6 ± 5.7 nm (Figure 3(d)) character-
istic of small EVs. The total number of particles varied
strongly between individuals and in mean remained
constant during exercise between pre-, RQ 0.9 and
Figure 3. SEC-isolation of EVs. (a,b) NTA (bars) and protein content (line) of SEC fractions as well as WB analysis of SEC fractions
using genuine EV-markers (CD9, CD63, CD81), a platelet-specific marker (CD41b) and Apolipoprotein A1 (ApoA1) as lipoprotein
marker. Fractions 4 to 6 (= SEC-EVs) are considered EV-rich while plasma protein- and lipoprotein-poor. (c) Transmission electron
microscopy image of SEC-EVs. Scale bar refers to 200 nm. (d) Representative NTA size distribution profile of SEC-EVs collected pre, at
RQ 0.9 and post-exercise. (e) NTA total particle counts in SEC-EVs collected pre, at RQ 0.9 and post-exercise (SEM, n = 7).
Figure 2. EV Array analysis of plasma EVs from exercising humans. (a) Heatmap of EV Array markers that change in relative intensity during
exercise. Markers depicted were higher than the LOD in more than 50% of cases. (b) Fold changes of significantly increasing markers
depicted with 95%-confidence intervals (CI). Bonferroni-corrected students t-test, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, n = 10.
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post-exercise samples (Figure 3(e)). It is well estab-
lished that NTA depicts lipoprotein particles in addi-
tion to EVs, not allowing the correct enumeration of
plasma EVs [36–38]. Hence, we conclude that NTA is
not a suitable technique to depict EV-dynamics during
exercise even in fasted subjects, due to a large non-EV
related particle background in plasma.
We further examined the exercise-associated kinetics
of EV-markers in SEC-EVs. WB analysis of SEC-EVs
revealed that, normalized to plasma volume, EV-
associated proteins rise from pre to RQ 0.9 and post-
exercise (Figure 4(a,b)). Significant increases of roughly
twofold were observed for the tetraspanins CD9, CD63
and CD81 post-exercise, which was already visible as
slight elevation above baseline at submaximal loads at
RQ 0.9. Similarly, the more specific markers for late
endosome-derived small EVs TSG101 and Syntenin
showed a trend to increase in response to exercise.
Furthermore, CD41b, specifically depicting platelet-
derived EVs, was significantly increased by 2.4-fold post-
exercise. Markers representative of EVs derived from
exercise-related cell types such as muscle cells [alpha-
sarcoglycan, [39], Figure 4(a)] or hepatocytes (asialogly-
coprotein receptor, not shown) could not be detected. In
addition, non-EV-markers such as the ER-membrane
protein Calnexin were not detected in SEC-EVs (data
not shown). In contrast to EV-markers, ApoA1 indicat-
ing co-isolating HDL particles remained unchanged in
ExerV samples. Of note, detection of EVs was dependent
on limited levels of lipoprotein contamination in SEC
fractions, as intake of a meal containing a high amount
of fat prior to the exercise interfered with EV character-
ization methods (Figure 4(c,d)). In postprandial condi-
tions, Western Blot detection of EV-epitopes was
hampered (Figure 4(c)). In addition, particle counts
in SEC-EVs were affected by an order of magnitude
Figure 4. Quantitative analysis of SEC-isolated ExerVs. (a) Representative WB analysis of SEC-EVs (pooled fractions 4–6) using EV-
markers, muscle marker alpha-sarcoglycan (SGCA) and lipoprotein marker ApoA1. (b) Densitometric quantification of WB signals.
Individual (circle) and mean (bar) fold changes of WB markers. RQ 0.9 and post expressed in relation to pre-exercise (dashed line).
Bonferroni-corrected students t-test, n = 7–11, *** = p < 0.001. (c, d) WB analysis and NTA of SEC-EVs of one study subject after
fasting and a high-fat meal. Number of particles increase by an order of magnitude while WB signals diminish upon high-fat diet.
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(Figure 4(d)), again highlighting the fact that NTA parti-
cle counts of plasma EVs are largely dominated by lipo-
protein particles and are unrelated to EV-dynamics.
In summary, Western Blot analysis of SEC-isolated
EVs employing several EV-markers indicated an
increase of ExerVs in plasma after acute cycling exer-
cise, consistent with our previous study employing
ultracentrifugation for EV isolation [12]. However,
markers more typical for late endosome-derived small
EVs appeared less prominently increased among
ExerVs as opposed to the tetraspanins CD9, CD63
and CD81.
Multiplex phenotyping of SEC-isolated ExerVs
To further specify ExerVs and their parental cells, we
performed a phenotyping analysis of ExerVs released
from pre to post-exercise to reveal cell-type specific
marker changes during exercise. To this end, we uti-
lized the MACSPlex platform, which consists of
a multiplexed, bead-based assay followed by flow cyto-
metric evaluation [40]. EVs are first captured by col-
our-coded beads carrying different marker-specific
antibodies and then detected by a mixture of antibodies
recognizing the EV-proteins CD9, CD63 and CD81
(Figure 5(a)). MACSPlex analysis of SEC-isolated EVs
revealed surface marker profiles characterized by
strong signals for platelet-associated markers (e.g.
CD42a and CD62P) and for leukocyte markers such
as CD8 and HLA-DRDPDQ (MHC-II) next to the
typical EV-proteins CD9, CD63 and CD81 (a represen-
tative profile is shown in Figure 5(b)).
Relative changes in signal intensities of specific mar-
kers between pre, RQ 0.9 and post-exercise SEC-EVs
provide information on the release kinetics and cellular
origin of ExerVs liberated into the circulation. Heatmap
visualization of marker dynamics in individuals identi-
fied a panel of markers increasing during exercise
(Figure 5(c)). However, the recorded fold changes are
moderate for most of the subjects, although few subjects
exhibit robust marker increases (S4, S19, S24).
Regarding longitudinal individual changes, increases
are consistently stronger post-exercise as compared to
the intermediate RQ 0.9 time point (reflected by their
position more to the right in the heatmap). While RQ
0.9 and post-exercise samples do not perfectly cluster
into two branches, clustering appears to separate high-
responders (S4, S19, S24), moderate responders (S14,
S17, S18) and non-responders (S5, S16). This finding
suggests that ExerVs exhibit different EV release kinetics
among individuals.
On the single marker level, EV-markers such as the
tetraspanins CD9, CD63 and CD81 or platelet-derived
CD41b were significantly elevated post-exercise by 1.3
to 1.6-fold (Figure 5(d)). These values appear smaller
as compared to the increases in these markers deter-
mined by WB in the same samples (Figure 4(b)). This
may be explained by competition of bead-coupled anti-
bodies and detection antibodies for the same epitopes
in case of the tetraspanins [41], or by masking of
epitopes by plasma constituents such as lipoproteins
possibly resulting in generally weakened signal inten-
sities in bead-based assays as opposed to WB detection.
In general, semi-quantitative data achieved by WB
were more robust as compared to MACSPlex analysis
of SEC-EVs, indicating a potential for further optimi-
zation of multiplexed work-flows.
In addition to EV-markers, several cell-type or line-
age-specific surface markers showed low but significant
increases upon exercise. Platelet markers (e.g. CD42a and
CD62P) or leukocyte-associated proteins (e.g. CD29,
CD69 and MHC-II) showed average fold changes
between 1.3 and 1.8-fold, with CD62P significantly ele-
vated even at RQ 0.9 (Figure 5(e)). Endothelial markers
CD105 andCD146 were increased to slightly higher levels
post-exercise by 2.3- and 2.0-fold, respectively.
Intriguingly, the lymphocyte and monocyte markers
CD4 and CD14 were repeatedly only detectable after
exercise while being under or near detection threshold
before exercise (see Figure 5(b)). The relatively highmean
fold changes and degree of variance (Figure 5(e)) may be
related to the fact that some pre-exercise samples were
below the limit of quantification for these markers.
However, the constant observation of CD4- and CD14-
EVs after exercise strongly suggests the release of
a relevant EV-population likely originating from lympho-
cytes and monocytes. In summary, phenotyping of
SEC-isolated ExerVs reveals surface marker dynamics
providing evidence for their origin largely from platelets,
leukocytes including lymphocytes and monocytes, and
endothelial cells.
ExerVs comprise CD9+, CD63+ and CD81+
EV-populations
To gain insight in potential ExerV-subclasses, we per-
formed immuno-isolation of EVs from the unprocessed
plasma of exercising subjects using CD9-, CD63- or
CD81-antibody-coupled magnetic beads resulting in
defined populations of CD9+EVs, CD63+EVs or
CD81+EVs. However, bead-isolation is incompatible
with NTA as intact EVs cannot be eluted from the
isolation beads efficiently. Western Blot analysis of bead-
isolated CD9+EVs, CD63+EVs and CD81+EVs con-
firmed the presence of CD9, CD63, CD81 as well as
Syntenin in all three EV-populations while TSG101 was
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not detectable (Figure 6(a)). As reported for SEC-EVs,
alpha-sarcoglycan representative of muscle-derived EVs
and hepatic markers were undetectable in the isolated
EVs. Interestingly, ApoA1 was largely absent from
bead-isolated EVs, indicating efficient removal of lipo-
proteins. Consistent with the results obtained with SEC-
isolation, bead isolation resulted in increased recovery of
EVs during and after exercise (Figure 6(b-d)). Overall,
EV-markers were similarly represented in CD9+EVs,
CD63+EVs and CD81+EVs. While CD9, CD63 and pla-
telet CD41b showed a clear trend or were significantly
increased during exercise, CD81 and Syntenin were not
or less affected. Isolation of CD81+EVs resulted in sig-
nificant gradual increases of EV-markers from pre to
Figure 5. Phenotyping of SEC-isolated ExerVs by MACSPlex analysis. (a) Principle of the MACSPlex assay: Isolated EVs are captured
by colour-coded beads carrying specific antibodies for cell surface markers. Subsequently, detection antibodies for the EV-markers
CD9, CD63 and CD81 conjugated to APC bind to the EVs. Read-out is achieved by flow cytometry revealing the surface marker
profile of EV-samples. (b) Mean fluorescence intensities (MFI) displayed in MACSPlex analysis of SEC-EVs isolated from plasma of one
representative exercising subject. (c) Heatmap visualization of individual MACSPlex marker increases in SEC-EVs including hier-
archical clustering for markers as well as subjects. Log2-fold changes of MFI at RQ 0.9 and post in relation to pre-exercise are
presented. (d, e) Mean tetraspanin and selected cell surface marker elevations with 95%-CI during exercise. Bonferroni-corrected
students t-test, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, n = 8.
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RQ 0.9 to post-exercise, with platelet CD41b most pro-
minently affected (Figure 6(d), CD9 1.8-fold; CD63
1.9-fold, CD41b 8.6-fold).
ExerVs originate from platelets, leukocytes and
endothelial cells
Immuno-bead isolated CD9+-, CD63+- and CD81+-
ExerV populations were further phenotyped by
MACSPlex analysis (Figure 7). Compared to SEC-
EVs (Figure 5(b)), more markers with robust signal
intensities are represented in the profile (Figure 7(a)).
As already described by others [40,41] CD9, CD63
and CD81 are barely detectable in the respective
CD9+-, CD63+- and CD81+ EV-population, although
cross-detection is well achieved (e.g. CD63 is not
detected in CD63+EVs but very well in CD81+EVs).
This is explained by epitope competition, when cap-
ture bead and detection bead target the same tetra-
spanin and hence, does not indicate the absence of the
respective tetraspanin. Comparing overall surface
marker profiles, CD63+EVs and CD81+EVs exhibit
a strikingly similar pattern characterized by high sig-
nal intensities for platelet (e.g. CD42a), endothelial
(e.g. CD105) and leukocyte markers (e.g. CD40).
Signal intensities achieved with CD9+EVs are gener-
ally lower. However, the relative representation of
CD62P and HLA-DRDPDQ (MHC-II) appears higher
among CD9+EVs as compared to CD63+EVs and
CD81+EVs, which was also noticeable in SEC-EVs
(Figures 5(b) and Figure 7(a)). Heatmap illustration
of marker changes across all subjects again confirms
incremental marker increases from pre to RQ 0.9 and
post-exercise (Figure 7(b)). Clustering analysis largely
groups RQ 0.9 samples left to respective post samples
reflecting stable release kinetics and marker pheno-
types of ExerVs among individuals. In addition, low
responder (e.g. S3) and high responder subjects are
clearly separated (e.g. S14, S15, S23).
Intriguingly, markers found with significant fold
change increases were highly congruent between
CD9+-, CD63+- and CD81+ExerVs (Figure 8(a-c)),
Figure 6. Quantitative WB analysis of immunobead-isolated ExerVs. (a) Representative WB analysis of CD9+EVs, CD63+EVs and
CD81+EVs using EV-markers and lipoprotein marker ApoA1. (b-d) Densitometric quantification of WB signals. Individual (circle) and
mean (bar) fold changes of WB markers in (b) CD9+EVs, (c) CD63+EVs and (d) CD81+EVs. RQ 0.9 and post expressed in relation to
pre-exercise (dashed line). Bonferroni-corrected students t-test, n = 2–7, * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
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suggesting that the contributing cells release EVs con-
taining all three tetraspanins (combined in single EVs
or in different individual EVs). Overall, markers exhib-
ited a trend to increase at RQ 0.9 (marking the onset of
ExerV-release) and significant mean fold increases ran-
ging from 1.4 to 10.4-fold after exercise. Similar to
SEC-EVs, CD4 and CD14 were barely present before
but reproducibly detected after exercise (Figure 7(a)),
reflected in large fold change increases (Figure 8(a-c)).
CD63+ExerVs as well as CD81+ExerVs were signifi-
cantly elevated in platelet-specific markers (CD41b,
CD42a, CD62P, between 1.8 and 2.9 fold in mean),
lymphocyte markers (CD4, 10-fold and CD8 1.5-2
fold), MHC-I (2.5–3 fold) and markers specifying anti-
gen-presenting cells (APC) (MHC-II, CD40, between
2.4- and 3.4 fold in mean). In addition, endothelial
markers such as CD31 (2.5–3.7 fold), CD105 (3.2–4.3
fold) and CD146 (3.3-3.5 fold) increased significantly
with exercise (Figure 8(b,c)). In CD9+ExerVs (Figure 8
(a)), similar but fewer EV-associated markers reach
statistical significance, probably due to the smaller
sample size (n = 5). Significant increases were again
Figure 7. MACSPlex phenotyping of CD9+-, CD63+- and CD81+ExerVs. (a) Representative mean fluorescence intensities (MFI) of
markers determined in MACSPlex analysis of immunobead-isolated CD9+EVs, CD63+EVs and CD81+EVs. (b) Heatmap visualization of
individual surface marker increases in immunobead-isolated ExerVs including hierarchical clustering for markers as well as subjects.
Log2-fold changes of MFI at the RQ 0.9 level and post-exercise in relation to pre-exercise are presented.
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observed for lymphocyte (CD4 and CD8), endothelial
(CD105 and CD146), APC (MHC-II and CD40) and
platelet markers (CD62P), although CD41b and CD42a
changes were not within statistical significance for
CD9+-ExerVs. Taken together, these findings reveal
that immunobead isolation results in efficient isolation
of ExerVs, which appear to represent a mixture of all
three CD9+, CD63+ and CD81+ subtypes exhibiting an
overall similar phenotype.
In summary, data collected using different EV-
isolation and phenotyping strategies identify
a reproducible ExerV marker pattern (Figure 9)
providing evidence that ExerVs constitute a mixed
population of EVs originating at least partially from
leukocytes (including lymphocytes, monocytes and
APC), endothelial cells and platelets.
Discussion
Our study provides novel insights regarding the pur-
ification, characterization and origin of EVs released
during physical exercise (ExerVs). Using stringent
methodology for purification of EVs from plasma
(SEC and immuno-isolation), we identified by semi-
Figure 8. MACSPlex marker kinetics of CD9+-, CD63+- and CD81+ExerVs. (a-d) Mean cell surface marker elevations with 95%-CI at RQ
0.9 and post-normalized to pre-exercise in (a) CD9+EVs (n = 5), (b) CD63+EVs (n = 7) and (c) CD81+EVs (n = 9). Individual values of
biological replicates in Figure 7. Bonferroni-corrected students t-test, * = p < 0.05, ** = p < 0.01, *** = p < 0.001.
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quantitative means an ExerV marker-profile that is
highly consistent between different isolation proce-
dures (Figure 9). The ExerV profile hence appears
highly reliable and indicates that endothelial cells, pla-
telets and different subsets of leukocytes, including
T-cells and antigen-presenting cells, release EVs upon
exercise stimulation. EVs liberated during exercise
were hypothesized to be involved in multisystemic
signalling mediating regeneration and long-term adap-
tive responses [11–14,42,43]. Physical exercise pro-
duces an elevated level of shear-stress, as well as
higher concentrations of reactive oxygen species [44]
and release of catecholamines [45]. Furthermore, the
activation of the hypothalamus-pituitary-adrenal axis
including an increase of cortisol levels in the circula-
tion can be observed upon exercise [46]. These acute
physiological alterations are accompanied by pro-
thrombic as well as fibrinolytic reactions [47],
enhanced endothelial functions [48] and the induction
of an acute inflammatory reaction [31,49]. As
a consequence, communication between several tissues
and cells is required to maintain whole-body home-
ostasis and to restore or further enhance systemic per-
formance levels. The finding that ExerVs in part
originate from cells of the circulatory system is consis-
tent with the notion that ExerVs may play a role in
exercise-triggered processes such as improved cardio-
vascular function, immune-modulation, inflammation-
associated tissue regeneration and regulation of
coagulation, which were ascribed to EVs previously in
other settings [reviewed in 7]. Which signals trigger the
release of ExerVs from all these cell types and the target
cells still remains to be elucidated.
Intriguingly, exercise leads to the liberation of EVs
starting already at sub-maximal workload-levels.
Similar to releases of cfDNA by exercise [30,50],
increases of EVs can be observed within just a few
minutes upon start of exercise in the aerobic–anaerobic
transition state around the individual anaerobic thresh-
old (IAT) with an RQ around 0.9. We regard these
rapid releases of EVs as a first hint that ExerVs are
released from cells that are not separated by the blood-
tissue barrier. However, our phenotyping analysis was
limited to a restricted marker panel represented in the
multiplexed assay. Hence, we possibly could not define
all cell populations contributing to the pool of ExerVs.
Red blood cells and muscle cells, which are known to
release EVs under various conditions [51,52], consti-
tute potential ExerV sources. Yet, we did not find
evidence that muscle cells or hepatic cells contribute
to the ExerV pool in our exercise setting. In a recent
study using acoustic trapping, ExerVs have been stu-
died 1 h after exercise [53]. Similar to us, the group
reported the release of protein cargo of the respective
ExerVs that mostly reflect proteins known to be
released or expressed by either blood cells, or the
endothelium. While this and our study points to
a significant contribution of circulation-associated
Figure 9. Venn diagram summarizing ExerV-phenotyping. Circles depict unique and shared ExerV-markers that were significantly
increased in the different isolation and characterization strategies (EV Array versus SEC-EVs versus bead-isolated EVs). Unique
markers are only associated with EV Array performed on total plasma, while the different EV-isolation strategies, including bead-
isolated EV-populations, largely share the same markers.
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cells to the ExerV pool, further studies are required to
uncover the full spectrum of ExerV sources and their
specific content.
Another exciting aspect revealed by our study is that
the level of ExerV-release varies between subjects, dis-
criminating low responders and high responders.
Although the factors contributing to this individual
variation remain enigmatic, it can be expected that EV-
release depends on the physiological background of the
subjects and may be influenced by parameters like age,
immune status, hormone levels or the metabolic state.
It will be interesting to correlate the level of ExerV-
release with different blood parameters and the ability
of the individuals to respond to long-term training.
However, we cannot completely rule out at present
that ExerV measurement is influenced by pre-
analytical factors. This may include factors present in
the exercised blood like stress hormones that may
affect cell activation and ExerV release status ex vivo
especially in post-exercise samples. Yet, according to
the existing literature [23,24], minor delays in plasma
processing in presence of the anticoagulant EDTA (as
occurred in our study) is not expected to affect the
release of EVs from platelets or other cells.
We characterized ExerV presence and dynamics
using two multiplexed marker assays and verified spe-
cific EV-markers by Western blotting, applying blood
plasma (EV-Array) as well as SEC-isolated EVs,
CD9+EVs, CD63+EVs and CD81+EVs. We obtained
consistent results for EV-dynamics and the origin of
ExerVs in all parallel examinations emphasizing the
strength of the analysis and reliability of the results.
The use of multiplexed assays offered the possibility to
analyse a variety of markers in limited sample material
to gain more detailed information on the cellular
source of ExerVs. Yet, these are semi-quantitative anti-
body-based workflows that are susceptible to bias
introduced by antibody affinity and possible epitope
blocking [41]. The longitudinal analysis of plasma sam-
ples derived from one individual within less than 1 h
allows interpretation of ExerV release kinetics on the
level of single markers but may be limited with regard
to a direct quantitative comparison of different mar-
kers. Furthermore, increase in marker signal intensity
can be related to higher vesicle numbers or higher
marker density in the vesicles. Since marker increases
are observed within minutes during exercise, most
likely the level of EV-release is increased in responsive
cell populations resulting in a higher number and an
altered mix of EVs in the circulation upon stimulation
by exercise. Finally, more detailed insight into ExerV
dynamics will require further development of high
throughput single EV-analysis techniques that allow
reliable detection of EVs also in the size range of
small EVs around or below 200 nm [54,55].
Intriguingly, we observed only a few differences in
the surface signatures and kinetics of the differentially
isolated ExerVs. For example, EVs derived from acti-
vated platelets appeared more prominent in SEC-EVs
and CD9+EVs as compared to CD63+EVs and
CD81+EVs. This underscores the reliability of our
ExerV isolation workflows and is in contrast to
a growing number of studies applying different EV
isolation strategies on the same sample material and
reporting strikingly diverse downstream analysis
results. For example, van Deun et al. demonstrated
a bias on the analysis of the EV mRNA profiles com-
paring differential centrifugation precipitation and
density gradient purification of EVs [56], emphasizing
the need for more coherent criteria of EV isolation.
In agreement with other studies, our study suggests
that NTA analysis of plasma EVs is strongly affected by
circulating lipoproteins that co-purify with EVs. NTA
was not able to resolve the more than twofold increase
in ExerVs detected by other marker-based analyses.
Furthermore, we observed strong differences in abso-
lute particle concentrations of SEC-EVs using NTA
after intake of a high-fat meal prior to the exercise
test compared to fasting conditions. Although this
effect was assessed for only one subject by directly
comparing pre- and postprandial conditions, it is in
line with the general view on the bias introduced by co-
isolated chylomicrons and lipoproteins in plasma EV
samples [36,38]. Sodar et al. demonstrated that lipo-
proteins co-purify with and decorate EVs interfering
with vesicle analysis. Similarly, for differential centrifu-
gation of blood plasma EVs it was recently demon-
strated that 66% of the variation in particle
concentration in the postprandial state measured by
NTA can be attributed to VLDL co-isolation [37].
We, therefore, caution that current NTA-technology
(not involving specific marker detection) is not reliable
in determining dynamic alterations of plasma EVs and
produces misleading results even on SEC isolated
plasma EVs. Variations in EV particle counts have to
be validated by EV-marker analysis.
Our data are in accordance with the characteristics
of EV-release in response to exercise described in the
present literature and provides comprehensive infor-
mation on the composition of ExerV populations ori-
ginating from distinct parental cells. A group of studies
focused on the role of large microparticles (MP) pre-
sent in the circulation upon physical activity. In total,
these studies report a short-term rise in pro-coagulative
MPs originating from activated platelets during and
few hours after exercise [57–59] as well as increasing
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endothelial cell MP-levels 24 h following an acute bout
of exercise, which is attributed to apoptotic processes
[59, reviewed by 15]. Two studies additionally observed
the release of MP from monocytes [59] and neutrophils
[57]. Changes in MP counts were analysed by conven-
tional flow cytometry focusing on endothelial and pla-
telet characteristics. Since these measurements are
restricted to EVs above the size of 500 nm and small
EVs will be under-represented, it is unclear to what
extend smaller EVs below 500 nm actually contribute
to vesicle enumeration in these studies [60,61]. A few
studies focus on the presence of small EVs in the
circulation after physical activity by applying single
particle analysis methods and the examination of the
protein content. An increase of EV numbers upon
bouts of acute exercise was repeatedly reported despite
a lack of consistent isolation strategies. More specific
analyses addressed contribution of muscle cell-derived
EVs to the pool of plasma EVs and were directed on
the possible regenerative functions of small EVs
released upon exercise [10–14,39,43,62]. Recently,
Whitham et al. postulated a model of exercise-
mediated tissue cross-talk, including systemic release
of EVs in response to exercise, myokine transport in
EVs originating from muscle cells and ExerV-uptake in
the liver [14]. The study provides a systematic proteo-
mic characterization of a crude EV preparation
retrieved by low-speed centrifugation that was postu-
lated to reflect small EVs but lacks characterization of
released EV-types and the contribution of different
parental cells.
Our study aimed at a broader phenotyping of
ExerVs allowing allocation of ExerV origin and the
initial identification of markers that may give further
indications of ExerV function. The elevation of
CD41b-, CD42a- and CD62P-positive platelet EVs
indicates that liberation of EVs by activated platelets
is not restricted to large EVs (>500 nm) but also
includes smaller EV populations. Furthermore,
CD31- (shared by platelets and endothelial cells),
CD105- and CD146-positive endothelial EVs, are
increasing immediately after exercise demonstrating
endothelial ExerV-release that can be clearly discrimi-
nated from apoptosis, which would lead to higher EV
counts only at later stages. Interestingly, a fraction of
ExerVs appears to originate from leukocytes including
lymphocytes (CD4+ and CD8+ExerVs), monocytes
(CD14+ExerVs) and antigen-presenting cells (MHC-
II+ExerVs) which, except for monocytic origin of
MPs, has not been described before. Information on
ExerV origin and their marker profile are essential to
address specific questions also with regard to their
function. However, it is important to consider that
only a few markers are exclusively found on the sur-
face of only one cell type. While platelet markers and
lymphocytic markers are highly specific, e.g. CD105
and CD146, prominently found on endothelial cells
and EVs, are also present on mesenchymal stromal
cell subtypes and their EVs [63–65]. Likewise, CD14 is
mainly associated with monocytes/macrophages, but
also present on the surface of neutrophils, though at
lower levels [66]. Analyses in a more defined setting
using further isolated EV subclasses to avoid expected
confounding effects of heterogeneous EV-mixtures
[67] will further shed light on the complex composi-
tion of ExerVs and their possible functions. Of note,
integrins such as CD29 (integrin β-1), CD41b (integ-
rin αIIβ) and CD49e (integrin α-5) are found on the
surface of all ExerV subclasses and could play a role
for the targeting selectivity of ExerVs. Together, these
findings highlight the complexity of EV signalling
during exercise and expand the spectrum of concei-
vable functions of ExerVs.
In conclusion, we provide evidence for ExerV-origin
at least in part from various cell types of the circulatory
system, verified by different procedures of EV isolation
and characterization. This finding suggests a complex
EV-signalling network with potential implications in
vascular functionality, immune modulation including
adaptive immunity, platelet function and regeneration.
Future studies are required to unravel potential other
ExerV sources, their specific role in tissue crosstalk and
mode of action in target cells. Identification of ExerV
signalling mechanisms associated with adaptational
benefits of exercise may translate into future diagnostic
and therapeutic applications of ExerVs.
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